|
|
Increasing the health equity and population-level impact of a digital therapeutic for smokers with psychiatric illness |
| 1K02DA054304-01A1 |
|
NIDA |
2022 |
|
|
Impact of Medicare Part D opioid safety policies on disabled beneficiaries before and during the COVID-19 pandemic |
| 1R01DA055131-01 |
|
NIDA |
2022 |
|
|
Improving MOUD Access, Opioid-Related Outcomes and Equity Among Medicare Beneficiaries with Disability |
| 1R01DA057568-01 |
|
NIDA |
2022 |
|
|
Social determinants of substance use disorder treatment outcomes in a vulnerable population |
| 1R21DA055229-01 |
|
NIDA |
2022 |
|
|
A telehealth tDCS approach to decrease cannabis use: Towards reducing multiple sclerosis disability in multiple sclerosis |
| 1R21DA055427-01 |
|
NIDA |
2022 |
|
|
Psychostimulants, Attention Deficit and Basal Ganglia Disorders |
| 1R21DA055980-01 |
|
NIDA |
2022 |
|
|
Dissecting functional roles of MeCP2 condensates in neurons with chemogenetic tools |
| 1R21DA056293-01 |
|
NIDA |
2022 |
|
|
Identification of small molecules for neurological complications of HIV and substance abuse comorbidity |
| 3R01DA046204-05S1 |
|
NIDA |
2022 |
|
|
Epigenetic mechanisms underlying cannabinoid modulation of neuroinflammation in HIV/SIV infection-supplement |
| 3R01DA052845-03S1 |
|
NIDA |
2022 |
|
|
Effectiveness, toxicity and safety of opioid and benzodiazepine substitutes |
| 5R01DA039192-07 |
|
NIDA |
2022 |
